The company has agreed to acquire Heumann Pharma GmbH & Co Generica KG through its wholly owned German subsidiary, Torrent Pharma said.
The company, however, did not disclose the financial details of the proposed acquisition.
The acquisition will exclude manufacturing facilities, which will be retained with Heumann PCS GmbH, a wholly owned sunsidiary of Pfizer, the statement said. Heumann Pharma had a sales of 50 million euro for the fiscal ended November 2004, the statement said.
As a part of the agreement, Heumann Pharma Generics would continue to procure part of its requirements of formulations from Heumann PCS for a specified period, it said.
Support services will also be provided by Pfizer entities in Germany till April 2006 to facilitate smooth transition, it said.
The acquisition is expected to give Torrent access not only to Heumann's brand, but also 315 marketing authorisations and 34 product registration applications, it said.
Heumann has a strong presence in generic medicines segment with a present product portfolio consisting of 116 products, predominantly sold under prescription, it said.
The acquisition, will, however be subject to regulatory approvals, which is expected to be completed by August this year, the company said.